Public-private partnerships in transplant drug development
Public-private partnerships in transplant drug development
复制标题
DOI：
10.1111/ajt.15604
复制
发表时间：
2019-10-30
影响因子：
8.8
通讯作者：
Wang, Yaning
中科院分区：
文献类型：
--
作者：
Albrecht, Renata;Papadopoulos, Elektra J.;Wang, Yaning
由关键路径研究所 (C-Path) 领导的公私合作伙伴关系 (PPP) 移植治疗联盟 (TTC) 最近在《美国移植杂志》上发表了 Stegall 等人题为“药物安全性和耐受性在移植受者新免疫抑制疗法开发中的重要性”的白皮书。作为美国食品和药物管理局 (FDA)、药物评价与研究中心 (CDER)、新药办公室和转化科学办公室以及肿瘤学卓越中心的工作人员，我们希望就 TTC 的工作和白皮书提供我们的看法。
The Transplant Therapeutics Consortium (TTC), a public-private partnership (PPP) led by the Critical Path Institute (C-Path), recently published a whitepaper titled "The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients" by Stegall et al in the American Journal of Transplantation. As staff members of the Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs and Office of Translational Science, and the Oncology Center of Excellence, we would like to provide our perspective on the TTCs efforts and the whitepaper.